TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06490094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Description: The 8-week IBSR program is a clinical intervention based on The Work method, developed by Byron Katie and run in the US and Europe for 35 years. The IBSR intervention will involve weekly group meetings (3 hours/meeting) throughout 8 weeks. Home practice between sessions will be supported by facilitator assistants (1-hour session per week). All sessions will be standardized according to the IBSR certification program guidelines and will be assessed to maintain consistency in the program, as in previous studies. .
Study: NCT05703542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL701
Description: Tablet, taken Orally
Study: NCT04848909

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
Study: NCT05388006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05417997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kunamin®
Description: Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir
Description: Antiviral medication used to treat influenza

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Antiviral medication used to treat influenza

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: Anticoagulant medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Anticoagulant medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Analgesic to treat minor aches and pains, and fever reducer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Analgesic to treat minor aches and pains, and fever reducer.
Study: NCT06440278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Health and Depression (BA-HD)
Description: BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients will receive depression and heart disease education, as well as a list of local mental health resources.
Study: NCT04620941

Intervention type: DIAGNOSTIC_TEST
Intervention: reticulocyte/hemoglobin (Ret-He) ratio
Description: Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
Study: NCT06383949

Intervention type: DEVICE
Intervention: Synergy Cervical Disc system
Description: motion preservation disc

Intervention type: DEVICE
Intervention: Synergy Cervical Disc system
Description: motion preservation disc
Study: NCT06632236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.
Study: NCT05759156

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid injection
Description: The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
Study: NCT06361355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Post-change CMAB807
Description: for subcutaneous injection only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia
Description: for subcutaneous injection only
Study: NCT05260203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RITA (App)
Description: The RITA Remote Intelligence for Therapeutic Adherence application was designed, on the doctor's side, as a support for the management of the onco-hematological patient and, on the patient's side, as a first aid tool for the management of the most common problems, as well as an efficient and non-invasive means of communication with the doctor. The system also allows the caregiver and general practitioner to be included in the communication group.~The added value of the app consists in improving the relationship between the patient and the doctor, creating an effective communication channel, increasing the safety the patient has when facing his difficult path, reducing the number of visits to the facility and, in general, making those visits more efficient, thus creating savings both in terms of time and resources.
Study: NCT06248645

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
Study: NCT05417997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ceftriaxone/ Clarithromycin
Description: Inhibits the production of pneumolysin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone/ Clarithromycin
Description: Inhibits the production of pneumolysin
Study: NCT06248645

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
Study: NCT04587167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project ECHO
Description: Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project ECHO
Description: Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Announcement Approach Training
Description: Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Announcement Approach Training
Description: Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recall notices
Description: Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
Study: NCT06220526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Description: Transbronchial biopsy with Menghini-type or Franseen type Needle

Intervention type: DEVICE
Group type: OTHER
Intervention: endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Description: Transbronchial biopsy with Menghini-type or Franseen type Needle
Study: NCT02386007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-3101_150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-3101_300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-3101_600mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05434091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07291177
Description: PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07291177
Description: PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07291177
Description: PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
Study: NCT06292364

Intervention type: OTHER
Group type: OTHER
Intervention: immediate orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer immediately after debonding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
Study: NCT06363240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broadband Light
Description: Broadband Light treatment
Study: NCT04712734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: oral tablet, long-acting injection
Study: NCT05417997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Treat inflammation, severe allergies, flares of chronic illnesses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Treat inflammation, severe allergies, flares of chronic illnesses
Study: NCT04947150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Location-triggered notification
Description: If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflections on benefits of change
Description: Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach monitoring
Description: Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household support
Description: If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
Study: NCT06641934

Intervention type: OTHER
Intervention: No intervention; Observational study
Description: No intervention

Intervention type: OTHER
Intervention: No intervention; Observational study
Description: No intervention

Intervention type: OTHER
Intervention: No intervention; Observational study
Description: No intervention
Study: NCT06641297

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music video game
Description: The video game \&#39;Guitar Hero\&#39; will be used as the platform for training for participants to acquire a new \&#39;skill\&#39;

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music video game
Description: The video game \&#39;Guitar Hero\&#39; will be used as the platform for training for participants to acquire a new \&#39;skill\&#39;
Study: NCT06539260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Take 400 units of vitamin D3, twice daily, for a duration of 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
Study: NCT05536427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPM001
Description: IPM001 will be used against tumor cells
Study: NCT04901975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
Study: NCT05883800

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: On-couch adaptive radiotherapy
Description: A new treatment plan, guided by volumetric images, is created at each treatment session
Study: NCT06475677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoCor Advanced System
Description: The OrthoCor Advanced System is a portable battery-operated non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) plus heat therapy for general use pain relief. It utilizes a wrap that positions the device over painful areas and joint motion tracking recorded by a smart device application to monitor recovery metrics and therapy compliance.
Study: NCT05709002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MASP+
Description: mHealth (mobile app) for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A mobile app designed to assist the general population with smoking cessation.
Study: NCT04822298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 160
Description: AMG 160 administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 160
Description: AMG 160 administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 160
Description: AMG 160 administered as an intravenous (IV) infusion
Study: NCT04984356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WU-CART-007
Description: A single IV infusion of WU-CART-007 Cells on Day 1
Study: NCT05638854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB002
Description: ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB002
Description: ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously as per schedule specified in the respective arm.
Study: NCT05193942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Our Plan
Description: From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the intervention arm will be granted access and instructed to use the Our Plan program as directed. The Our Plan program includes modules covering topics of communication, decision-making, HIV/STI prevention, and stigma and discrimination. Each module contains content, questions, and activities for the participant and couple to complete. One goal of OurPlan is to help both partners of the couple create and use a risk- reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own confidence, intention, and perceived ability to use these strategies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internation Informational Control
Description: From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the informational control condition will receive a webpage that contains information about HIV/STI prevention options and resources. This control condition represents the current equivalent of a standard of care for online HIV resources.
Study: NCT06157892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: Given into the vein (IV; intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given twice daily by mouth (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given twice daily by mouth (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given twice daily by mouth (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given twice daily by mouth (orally)
Study: NCT04953156

Intervention type: DRUG
Intervention: Nitroglycerin
Description: data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.